Related Experiment Video
Updated: May 11, 2026

A Method for Evaluating Timeliness and Accuracy of Volitional Motor Responses to Vibrotactile Stimuli
Published on: August 2, 2016
Beyond empiric checkpoint escalation: Insights from KEYVIBE-010
Andrew Knight1, Ryan J Sullivan2
1Mass General Brigham Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Dana Farber Cancer Institute, Boston, MA, USA.
Abstract:
KEYVIBE-010 is a phase 3 trial evaluating the combination of adjuvant vibostolimab and pembrolizumab versus pembrolizumab in patients with resected, high-risk melanoma.1 It was stopped for futility, as the combination showed higher toxicity than pembrolizumab monotherapy without improved efficacy. These results reinforce the limited role for combined checkpoint inhibition in the adjuvant setting for patients with resected, high-risk melanoma.
More Related Videos
Related Concept Videos
Amplifying Signals via Enzymatic Cascade
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Desensitization and Tachyphylaxis
Several...
Therapeutic Drug Monitoring: Affecting Factors
GPCR Desensitization
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

